WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 573766
Description: AM-1710 is a cannabinoid CB2 agonist that has been shown to attenuate Morphine tolerance and withdrawal.
MedKoo Cat#: 573766
Chemical Formula: C23H28O4
Exact Mass: 368.1988
Molecular Weight: 368.47
Elemental Analysis: C, 74.97; H, 7.66; O, 17.37
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: AM-1710, AM1710, AM 1710
IUPAC/Chemical Name: 3-(1,1-Dimethylheptyl)-1-hydroxy-9-methoxy-6H-dibenzo(b,d)pyran-6-one
InChi Key: ZAIKPEWFCSQNQB-UHFFFAOYSA-N
InChi Code: 1S/C23H28O4/c1-5-6-7-8-11-23(2,3)15-12-19(24)21-18-14-16(26-4)9-10-17(18)22(25)27-20(21)13-15/h9-10,12-14,24H,5-8,11H2,1-4H3
SMILES Code: CCCCCCC(C)(C)c1cc(O)c2c(OC(=O)c3ccc(OC)cc23)c1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 368.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, Hohmann AG. Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal. Mol Pharmacol. 2019 Feb;95(2):155-168. doi: 10.1124/mol.118.113233. Epub 2018 Nov 30. PubMed PMID: 30504240; PubMed Central PMCID: PMC6324648.
2: Wilkerson JL, Gentry KR, Dengler EC, Wallace JA, Kerwin AA, Armijo LM, Kuhn MN, Thakur GA, Makriyannis A, Milligan ED. Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain. 2012 May;153(5):1091-106. doi: 10.1016/j.pain.2012.02.015. Epub 2012 Mar 17. PubMed PMID: 22425445; PubMed Central PMCID: PMC3603341.
3: Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav. 2011 Jun;98(4):493-502. doi: 10.1016/j.pbb.2011.02.024. Epub 2011 Mar 5. PubMed PMID: 21382397; PubMed Central PMCID: PMC3089437.